



an Open Access Journal by MDPI

In Vitro and In Vivo Approaches in the Driving Seat of Marine Drugs Discovery

Guest Editors:

Prof. Dr. Mei-Chin Lu

Graduate Institute of Marine
Biology, National Dong Hwa
University, Hualien 944, Taiwan

Dr. Mohamed El-Shazly

Department of Pharmacognosy,
Faculty of Pharmacy, Ain-Shams
University, Organization of
African Unity Street, Abassia,
Cairo 11566, Egypt

Dr. Kuei-Hung Lai

Graduate Institute of
Pharmacognosy, College of
Pharmacy, Taipei Medical
University, Taipei, Taiwan

Deadline for manuscript
submissions:

closed (10 June 2019)

Message from the Guest Editors

Despite three centuries of great scientific discoveries, the truth about oceans and their organisms remains elusive. Natural products, medicinal and synthetic chemists along with pharmacologists, biochemists, cell biologists and microbiologists united their forces to unleash hidden treasures of oceans and seas. New classes of secondary metabolites were discovered from marine organisms with an unprecedented spectrum of biological activities. Several compounds entered the drug pipeline and many others are in various stages of clinical trials. Scientists used all available biological assays to screen marine organism extracts and fractions to zoom in on the most important compounds.

This Special Issue of Marine Drugs entitled “In Vitro and In Vivo Approaches in the Driving Seat of Marine Drugs Discovery” focuses on presenting the most recent advances in biological assays applied for the discovery of marine secondary metabolites with potential biological activities. Full research papers and review articles reporting the applications of in vitro and in vivo assays to reveal biological activities of marine natural products, will be considered.



mdpi.com/si/10942

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Bill J. Baker

Department of Chemistry,
University of South Florida, 4202
E. Fowler Ave., CHE 205, Tampa,
FL 33620-5250, USA

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Embase](#), [PubAg](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))

Contact Us

Marine Drugs Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/marinedrugs
marinedrugs@mdpi.com
[X@Marine_Drugs](#)